Showing results (141-150 of 198) with videos related to
Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.International Journal of Radiation Oncology, Biology, Physics|May 1, 2020
Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate CancersIbrahim Abu-Gheida, Tharakeswara K Bathala, J Alberto Maldonado, et al.Molecular Cancer Research : MCR|August 31, 2021
Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate CancerShoujie Chai, Nicholas Matsumoto, Ryan Storgard, et al.JAMA Network Open|March 20, 2020
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate CancerAlexander F Bagley, Mitchell S Anscher, Seungtaek Choi, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 31, 2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesYago Nieto, Peter Thall, Ben Valdez, et al.Cell Reports|February 21, 2019
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder CarcinogenesisTadeusz Majewski, Hui Yao, Jolanta Bondaruk, et al.JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.Journal of Neurosurgery. Spine|June 14, 2024
Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approachThomas H Beckham, Michael K Rooney, Gizem Cifter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.Pageof 20